{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:11:40Z","timestamp":1779207100017,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232149"],"award-info":[{"award-number":["7232149"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073192"],"award-info":[{"award-number":["82073192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273231"],"award-info":[{"award-number":["82273231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62133010"],"award-info":[{"award-number":["62133010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["Z221100007422125"],"award-info":[{"award-number":["Z221100007422125"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04145-z","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:11:16Z","timestamp":1765959076000},"page":"2161-2173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic efficacy and oncological prognosis of ypTNM 0-I gastric cancer after neoadjuvant therapy: a multicenter propensity-score matched study in China"],"prefix":"10.1007","volume":"28","author":[{"given":"Hao","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiguang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1185-5322","authenticated-orcid":false,"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"4145_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4145_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond). 2024;44:127\u201372.","journal-title":"Cancer Commun (Lond)"},{"key":"4145_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"4145_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"4145_CR5","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330:2064\u201374.","journal-title":"JAMA"},{"key":"4145_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25:212\u201324.","journal-title":"Lancet Oncol"},{"key":"4145_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393:217\u201330.","journal-title":"N Engl J Med"},{"key":"4145_CR8","volume-title":"AJCC Cancer Staging Manual","author":"MB Amin","year":"2017","unstructured":"Amin MB, Gress DM. AJCC Cancer Staging Manual. Eight. New York: Springer; 2017.","edition":"Eight"},{"key":"4145_CR9","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1080\/0284186X.2023.2274480","volume":"62","author":"AD Sand\u00f8","year":"2023","unstructured":"Sand\u00f8 AD, Gr\u00f8nbech JE, Bringeland EA. Does the ypTNM-stage adequately predict long-term survival rates in gastric cancer patients receiving neoadjuvant chemotherapy followed by radical resection? Acta Oncol. 2023;62:1846\u201353.","journal-title":"Acta Oncol"},{"key":"4145_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12885-019-5283-3","volume":"19","author":"Z Li","year":"2019","unstructured":"Li Z, Wang Y, Ying X, Shan F, Wu Z, Zhang L, et al. Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis. BMC Cancer. 2019;19:80.","journal-title":"BMC Cancer"},{"key":"4145_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10120-017-0743-4","volume":"21","author":"N Ikoma","year":"2018","unstructured":"Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, et al. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018;21:74\u201383.","journal-title":"Gastric Cancer"},{"key":"4145_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"4145_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521\u201330.","journal-title":"Cancer"},{"key":"4145_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112:90\u20132.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"4145_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","journal-title":"Gastric Cancer"},{"key":"4145_CR16","first-page":"12029","volume":"12","author":"B Lian","year":"2020","unstructured":"Lian B, Chen J, Li Z, Ji G, Wang S, Zhao Q, et al. Risk factors and Clavien-Dindo classification of postoperative complications after laparoscopic and open gastrectomies for gastric cancer: a single-center, large sample. Retrospect Cohort Study Cancer Manag Res. 2020;12:12029\u201339.","journal-title":"Retrospect Cohort Study Cancer Manag Res"},{"key":"4145_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1405704","volume":"11","author":"H Cui","year":"2024","unstructured":"Cui H, Zhang S, Sun L, Yuan Z, Xu Q, Gao J, et al. Risk factor analysis and nomogram construction of postoperative complications for patients with locally advanced gastric cancer who received neoadjuvant immunotherapy and chemotherapy. Front Med (Lausanne). 2024;11:1405704.","journal-title":"Front Med (Lausanne)"},{"key":"4145_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goae005","volume":"12","author":"H Cui","year":"2024","unstructured":"Cui H, Liang W, Cui J, Song L, Yuan Z, Chen L, et al. Safety and feasibility of minimally invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer: a propensity score-matched analysis in China. Gastroenterol Rep. 2024;12:goae005.","journal-title":"Gastroenterol Rep"},{"key":"4145_CR19","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/JS9.0000000000002056","volume":"111","author":"Z Yu","year":"2024","unstructured":"Yu Z, Liang C, Xu Q, Yuan Z, Chen M, Li R, et al. The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis. Int J Surg. 2024;111:1415\u201326.","journal-title":"Int J Surg"},{"key":"4145_CR20","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1245\/s10434-020-09070-9","volume":"28","author":"Y Yan","year":"2021","unstructured":"Yan Y, Yang A, Lu L, Zhao Z, Li C, Li W, et al. Impact of neoadjuvant therapy on minimally invasive surgical outcomes in advanced gastric cancer: an international propensity score-matched study. Ann Surg Oncol. 2021;28:1428\u201336.","journal-title":"Ann Surg Oncol"},{"key":"4145_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","volume":"17","author":"X Wang","year":"2024","unstructured":"Wang X, Lu C, Wei B, Li S, Li Z, Xue Y, et al. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial. J Hematol Oncol. 2024;17:17.","journal-title":"J Hematol Oncol"},{"key":"4145_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00676-4","author":"X Zhang","year":"2025","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 2025. https:\/\/doi.org\/10.1016\/S1470-2045(24)00676-4.","journal-title":"Lancet Oncol"},{"key":"4145_CR23","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1245\/s10434-024-16408-0","volume":"32","author":"A Leng","year":"2025","unstructured":"Leng A, Madan V, Shah M, Gurau A, Johnston FM, Greer JB. Characterizing patients with ypT0N1 gastric adenocarcinoma within the AJCC staging system. Ann Surg Oncol. 2025;32:2122\u20138.","journal-title":"Ann Surg Oncol"},{"key":"4145_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goad070","volume":"11","author":"Q Chen","year":"2023","unstructured":"Chen Q, Xiao H, Zhang L, You J, Jin Z, Zhang B. Association between adjuvant chemotherapy and survival in stage I gastric cancer patients after curative resection. Gastroenterol Rep. 2023;11:goad070.","journal-title":"Gastroenterol Rep"},{"key":"4145_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1245\/s10434-024-16365-8","volume":"32","author":"Z Li","year":"2025","unstructured":"Li Z, Sun C, Fei H, Li Z, Zhao D, Guo C, et al. Downstaging effect rather than the full intended cycles of perioperative chemotherapy determines the value of adjuvant chemotherapy in gastric cancer. Ann Surg Oncol. 2025;32:342\u201350.","journal-title":"Ann Surg Oncol"},{"key":"4145_CR26","doi-asserted-by":"publisher","first-page":"7384","DOI":"10.21037\/tcr-20-2426","volume":"9","author":"K Zhu","year":"2020","unstructured":"Zhu K, Jin H, Zhang Q, Shou C, Chen F, Yu J. ypT0 gastric carcinoma after preoperative chemotherapy: a unique status according to AJCC 8(th) edition cancer staging system. Transl Cancer Res. 2020;9:7384\u201393.","journal-title":"Transl Cancer Res"},{"key":"4145_CR27","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s10147-023-02369-z","volume":"28","author":"F Guo","year":"2023","unstructured":"Guo F, Xiang X, Huang Y, Chen A, Ma L, Zhu X, et al. Long-term survival outcome of locally advanced gastric cancer patients who achieved a pathological complete response to neoadjuvant chemotherapy. Int J Clin Oncol. 2023;28:1158\u201365.","journal-title":"Int J Clin Oncol"},{"key":"4145_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189294","volume":"13","author":"Z Li","year":"2018","unstructured":"Li Z, Shan F, Wang Y, Zhang Y, Zhang L, Li S, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis. PLoS ONE. 2018;13:e0189294.","journal-title":"PLoS ONE"},{"issue":"2","key":"4145_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","volume":"30","author":"SQ Yuan","year":"2024","unstructured":"Yuan SQ, Nie RC, Jin Y, Liang CC, Li YF, Jian R, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med. 2024;30(2):552\u20139.","journal-title":"Nat Med"},{"key":"4145_CR30","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/bjc.2011.175","volume":"104","author":"RC Fields","year":"2011","unstructured":"Fields RC, Strong VE, G\u00f6nen M, Goodman KA, Rizk NP, Kelsen DP, et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104:1840\u20137.","journal-title":"Br J Cancer"},{"key":"4145_CR31","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.12998\/wjcc.v11.i27.6483","volume":"11","author":"Y Xing","year":"2023","unstructured":"Xing Y, Zhang ZL, Ding ZY, Song WL, Li T. Tumor recurrence after pathological complete response in locally advanced gastric cancer after neoadjuvant therapy: two case reports. World J Clin Cases. 2023;11:6483\u201390.","journal-title":"World J Clin Cases"},{"key":"4145_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00288","volume":"8","author":"EM Lander","year":"2024","unstructured":"Lander EM, Aushev VN, Huffman BM, Hanna D, Dutta P, Ferguson J, et al. Circulating tumor DNA as a prognostic biomarker for recurrence in patients with locoregional esophagogastric cancers with a pathologic complete response. JCO Precis Oncol. 2024;8:e2400288.","journal-title":"JCO Precis Oncol"},{"key":"4145_CR33","doi-asserted-by":"publisher","first-page":"6918","DOI":"10.1245\/s10434-024-15893-7","volume":"31","author":"Y Song","year":"2024","unstructured":"Song Y, Hirata Y, Ajani JA, Blum Murphy M, Li JJ, Das P, et al. Survival outcomes in patients with resectable gastric cancer treated with total neoadjuvant therapy. Ann Surg Oncol. 2024;31:6918\u201330.","journal-title":"Ann Surg Oncol"},{"key":"4145_CR34","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1002\/cncr.24396","volume":"115","author":"C Liebig","year":"2009","unstructured":"Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115:3379\u201391.","journal-title":"Cancer"},{"key":"4145_CR35","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1245\/s10434-020-08389-7","volume":"27","author":"BL Woodham","year":"2020","unstructured":"Woodham BL, Chmelo J, Donohoe CL, Madhavan A, Phillips AW. Prognostic significance of lymphatic, venous and perineural invasion after neoadjuvant chemotherapy in patients with gastric adenocarcinoma. Ann Surg Oncol. 2020;27:3296\u2013304.","journal-title":"Ann Surg Oncol"},{"key":"4145_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.acra.2024.07.051","volume":"32","author":"G Xu","year":"2025","unstructured":"Xu G, Feng F, Chen W, Xiao Y, Fu Y, Zhou S, et al. Development and external validation of a CT-based radiomics nomogram to predict perineural invasion and survival in gastric cancer: a multi-institutional study. Acad Radiol. 2025;32:120\u201331.","journal-title":"Acad Radiol"},{"key":"4145_CR37","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1007\/s00330-023-09464-9","volume":"33","author":"J Li","year":"2023","unstructured":"Li J, Xu S, Wang Y, Fang M, Ma F, Xu C, et al. Spectral CT-based nomogram for preoperative prediction of perineural invasion in locally advanced gastric cancer: a prospective study. Eur Radiol. 2023;33:5172\u201383.","journal-title":"Eur Radiol"},{"key":"4145_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7150\/jca.47899","volume":"12","author":"Q Cai","year":"2021","unstructured":"Cai Q, Zhou W, Li J, Ou X, Chen C, Cai S, et al. Association of preoperative serum carcinoembryonic antigen and gastric cancer recurrence: a large cohort study. J Cancer. 2021;12:397\u2013403.","journal-title":"J Cancer"},{"key":"4145_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512192","author":"XH Tang","year":"2023","unstructured":"Tang XH, Wu XL, Gan XJ, Wang YD, Jia FZ, Wang YX, et al. Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to predict and monitor the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241512192.","journal-title":"Int J Mol Sci"},{"key":"4145_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9:705\u201317.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4145_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41577-023-00884-8","volume":"23","author":"JM Schenkel","year":"2023","unstructured":"Schenkel JM, Pauken KE. Localization, tissue biology and T cell state\u2014implications for cancer immunotherapy. Nat Rev Immunol. 2023;23:807\u201323.","journal-title":"Nat Rev Immunol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04145-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04145-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04145-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:21Z","timestamp":1779204741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04145-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04145-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethic committee of the Chinese PLA general hospital (Approval No. S2024-498\u201301).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}